Immune modulation with sulfasalazine attenuates immunopathogenesis but enhances macrophage- mediated fungal clearance during pneumocystis pneumonia

PLoS Pathogens

Volumn 6, Issue 8, 2010, Pages 59-60

  Wang, Jing ^a   Gigliotti, Francis ^a   Bhagwat, Samir P ^a   George, Thaddeus C ^b   Wright, Terry W ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b Amnis Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SALAZOSULFAPYRIDINE; NONSTEROID ANTIINFLAMMATORY AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CELL POLARITY; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNITY; IMMUNOMODULATION; IMMUNOPATHOGENESIS; LUNG ALVEOLUS MACROPHAGE; MACROPHAGE; MOUSE; NONHUMAN; PHAGOCYTOSIS; PHENOTYPE; PNEUMOCYSTIS PNEUMONIA; T LYMPHOCYTE; TH2 CELL; ANIMAL; CELL SEPARATION; CONFOCAL MICROSCOPY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; IMMUNOLOGY; MACROPHAGE ACTIVATION; METHODOLOGY; MOUSE MUTANT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

MUS; PNEUMOCYSTIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CD4-POSITIVE T-LYMPHOCYTES; CELL SEPARATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNOMODULATION; MACROPHAGE ACTIVATION; MACROPHAGES, ALVEOLAR; MICE; MICE, SCID; MICROSCOPY, CONFOCAL; PHAGOCYTOSIS; PNEUMONIA, PNEUMOCYSTIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SULFASALAZINE;

EID: 77958125192     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1001058     Document Type: Article

References (83)

1. Santos J, Palacios R, Ruiz J, Gonzalez M, Marquez M (2005) Study of patients diagnosed with advanced HIV in the HAART era-OMEGA Cohort. Int J STD AIDS 16: 252-255.
2. Forrest DM, Seminari E, Hogg RS, Yip B, Raboud J, et al. (1998) The incidence and spectrum of AIDS-defining illnesses in persons treated with antiretroviral drugs. Clin Infect Dis 27: 1379-1385.
3. Staikowsky F, Lafon B, Guidet B, Denis M, Mayaud C, et al. (1993) Mechanical ventilation for Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. Is the prognosis really improved? Chest 104: 756-762.
4. Arend SM, Kroon FP, van't Wout JW (1995) Pneumocystis carinii pneumonia in patients without AIDS, 1980 through 1993. An analysis of 78 cases. Arch Intern Med 155: 2436-2441.
5. Kaur N, Mahl TC (2004) Pneumocystis carinii pneumonia with oral candidiasis after infliximab therapy for Crohn's disease. Dig Dis Sci 49: 1458-1460.
6. Sepkowitz KA, Brown AE, Armstrong D (1995) Pneumocystis carinii pneumonia without acquired immunodeficiency syndrome. More patients, same risk. Arch Intern Med 155: 1125-1128.
7. Morris A, Sciurba FC, Lebedeva IP, Githaiga A, Elliott WM, et al. (2004) Association of Chronic Obstructive Pulmonary Disease Severity and Pneumocystis Colonization. Am J Respir Crit Care Med 170: 408-413.
8. Benfield TL, van Steenwijk R, Nielsen TL, Dichter JR, Lipschik GY, et al. (1995) Interleukin-8 and eicosanoid production in the lung during moderate to severe Pneumocystis carinii pneumonia in AIDS: a role of interleukin-8 in the pathogenesis of P. carinii pneumonia. Respir Med 89: 285-290.
9. Jensen BN, Lisse IM, Gerstoft J, Borgeskov S, Skinhoj P (1991) Cellular profiles in bronchoalveolar lavage fluid of HIV-infected patients with pulmonary symptoms: relation to diagnosis and prognosis. AIDS 5: 527-533.
10. Limper AH, Offord KP, Smith TF, Martin WJ (1989) Pneumocystis carinii pneumonia. Differences in lung parasite number and inflammation in patients with and without AIDS. Am Rev Respir Dis 140: 1204-1209.
11. Lipschik GY, Doerfler ME, Kovacs JA, Travis WD, Andrawis VA, et al. (1993) Leukotriene B4 and interleukin-8 in human immunodeficiency virus-related pulmonary disease. Chest 104: 763-769.
12. Mason GR, Hashimoto CH, Dickman PS, Foutty LF, Cobb CJ (1989) Prognostic implications of bronchoalveolar lavage neutrophilia in patients with Pneumocystis carinii pneumonia and AIDS. Am Rev Respir Dis 139: 1336-1342.
13. Smith RL, El-Sadr WM, Lewis ML (1988) Correlation of bronchoalveolar lavage cell populations with clinical severity of Pneumocystis carinii pneumonia. Chest 93: 60-64.
14. Benfield TL, Vestbo J, Junge J, Nielsen TL, Jensen AB, et al. (1995) Prognostic value of interleukin-8 in AIDS-associated Pneumocystis carinii pneumonia. Am J Respir Crit Care Med 151: 1058-1062.
15. Vahid B, Bibbo M, Marik PE (2007) Role of CD8 lymphocytes and neutrophilic alveolitis in Pneumocystis jiroveci pneumonia. Scandinavian Journal of Infectious Diseases 39: 612-614.
16. Barry SM, Lipman MC, Deery AR, Johnson MA, Janossy G (2002) Immune reconstitution pneumonitis following Pneumocystis carinii pneumonia in HIV- infected subjects. HIV Med 3: 207-211.
17. Dore GJ, Li Y, McDonald A, Ree H, Kaldor JM (2002) Impact of highly active antiretroviral therapy on individual AIDS-defining illness incidence and survival in Australia. J Acquir Immune Defic Syndr 29: 388-395.
18. Wu AK, Cheng VC, Tang BS, Hung IF, Lee RA, et al. (2004) The unmasking of Pneumocystis jiroveci pneumonia during reversal of immunosuppression: case reports and literature review. BMC Infect Dis 4: 57.
19. Sharma S, Nadrous HF, Peters SG, Tefferi A, Litzow MR, et al. (2005) Pulmonary complications in adult blood and marrow transplant recipients: autopsy findings. Chest 128: 1385-1392.
20. Slivka A, Wen PY, Shea WM, Loeffler JS (1993) Pneumocystis carinii pneumonia during steroid taper in patients with primary brain tumors. Am J Med 4: 16-219.
21. Mansharamani NG, Balachandran D, Vernovsky I, Garland R, Koziel H (2000) Peripheral blood CD4 + T-lymphocyte counts during Pneumocystis carinii pneumonia in immunocompromised patients without HIV infection. Chest 118: 712-720.
22. Bachelez H, Schremmer B, Cadranel J, Mouly F, Sarfati C, et al. (1997) Fulminant Pneumocystis carinii pneumonia in 4 patients with dermatomyositis. Arch Intern Med 157: 1501-1503.
23. Sepkowitz KA (1993) Pneumocystis carinii pneumonia in patients without AIDS. Clin Infect Dis 17 Suppl 2: S416-S422.
24. Kovacs JA, Hiemenz JW, Macher AM, Stover D, Murray HW, et al. (1984) Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Ann Intern Med 100: 663-671.
25. Hori S, Carvalho TL, Demengeot J (2002) CD25+CD4+ regulatory T cells suppress CD4+ T cell-mediated pulmonary hyperinflammation driven by Pneumocystis carinii in immunodeficient mice. Eur J Immunol 32: 1282-1291.
26. Roths JB, Sidman CL (1992) Both immunity and hyperresponsiveness to Pneumocystis carinii result from transfer of CD4+ but not CD8+ T cells into severe combined immunodeficiency mice. J Clin Invest 90: 673-678.
27. Swain SD, Meissner NN, Harmsen AG (2006) CD8 T cells modulate CD4 T- cell and eosinophil-mediated pulmonary pathology in Pneumocystis pneumonia in B-cell-deficient mice. Am J Pathol 168: 466-475.
28. Wright TW, Gigliotti F, Finkelstein JN, McBride JT, An CL, et al. (1999) Immune-mediated inflammation directly impairs pulmonary function, contributing to the pathogenesis of Pneumocystis carinii pneumonia. J Clin Invest 104: 1307-1317.
29. Wright TW, Johnston CJ, Harmsen AG, Finkelstein JN (1999) Chemokine gene expression during Pneumocystis carinii-driven pulmonary inflammation. InfectImmun 67: 3452-3460.
30. Wright TW, Notter RH, Wang Z, Harmsen AG, Gigliotti F (2001) Pulmonary inflammation disrupts surfactant function during Pneumocystis carinii pneumonia. Infect Immun 69: 758-764.
31. Bhagwat SP, Gigliotti F, Xu H, Wright TW (2006) Contribution of T cell subsets to the pathophysiology of Pneumocystis-related immunorestitution disease. Am J Physiol Lung Cell Mol Physiol 291: L1256-L1266.
32. Roths JB, Sidman CL (1993) Single and combined humoral and cell-mediated immunotherapy of Pneumocystis carinii pneumonia in immunodeficient scid mice. Infect Immun 61: 1641-1649.
33. Swain SD, Han S, Harmsen A, Shampeny K, Harmsen AG (2007) Pulmonary Hypertension Can Be a Sequela of Prior Pneumocystis Pneumonia. Am J Pathol 171: 790-799.
34. O'Dell JR, Petersen K, Leff R, Palmer W, Schned E, et al. (2006) Etanercept in combination with sulfasalazine, hydroxychloroquine, or gold in the treatment of rheumatoid arthritis. J Rheumatol 33: 213-218.
35. Plosker GL, Croom KF (2005) Sulfasalazine: a review of its use in the management of rheumatoid arthritis. Drugs 65: 1825-1849.
36. Brookes MJ, Green JR (2004) Maintenance of remission in Crohn's disease: current and emerging therapeutic options. Drugs 64: 1069-1089.
37. Liptay S, Bachem M, Hacker G, Adler G, Debatin KM, et al. (1999) Inhibition of nuclear factor kappa B and induction of apoptosis in T-lymphocytes by sulfasalazine. Br J Pharmacol 128: 1361-1369.
38. Wang J, Gigliotti F, Maggirwar S, Johnston C, Finkelstein JN, et al. (2005) Pneumocystis carinii activates the NF-kappaB signaling pathway in alveolar epithelial cells. Infect Immun 73: 2766-2777.
39. Weber CK, Liptay S, Wirth T, Adler G, Schmid RM (2000) Suppression of NF-kappaB activity by sulfasalazine is mediated by direct inhibition of IkappaB kinases alpha and beta. Gastroenterology 119: 1209-1218.
40. Wahl C, Liptay S, Adler G, Schmid RM (1998) Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B. J Clin Invest 101: 1163-1174.
41. Evans SE, Hahn PY, McCann F, Kottom TJ, Pavlovic ZV, et al. (2005) Pneumocystis cell wall beta-glucans stimulate alveolar epithelial cell chemokine generation through nuclear factor-kappaB-dependent mechanisms. Am J Respir Cell Mol Biol 32: 490-497.
42. Lebron F, Vassallo R, Puri V, Limper AH (2003) Pneumocystis carinii cell wall beta-glucans initiate macrophage inflammatory responses through NF-kappaB activation. J Biol Chem 278: 25001-25008.
43. Zhang J, Zhu J, Imrich A, Cushion M, Kinane TB, et al. (2004) Pneumocystis activates human alveolar macrophage NF-kappaB signaling through mannose receptors. Infect Immun 72: 3147-3160.
44. Martinez FO, Helming L, Gordon S (2008) Macrophage activation and polarization. Annu Rev Immuno 27: 451-483.
45. Gordon S (2007) The macrophage: past, present and future. Eur J Immunol 37 Suppl 1: S9-17.
46. Cheng VC, Hung IF, Wu AK, Tang BS, Chu CM, et al. (2004) Lymphocyte surge as a marker for immunorestitution disease due to Pneumocystis jiroveci pneumonia in HIV-negative immunosuppressed hosts. Eur J Clin Microbiol Infect Dis 23: 512-514.
47. Chen CS, Boeckh M, Seidel K, Clark JG, Kansu E, et al. (2003) Incidence, risk factors, and mortality from pneumonia developing late after hematopoietic stem cell transplantation. Bone Marrow Transplant 32: 515-522.
48. Gan HT, Chen YQ, Ouyang Q (2005) Sulfasalazine inhibits activation of nuclear factor-kappaB in patients with ulcerative colitis. J Gastroenterol Hepatol 20: 1016-1024.
49. Baggott JE, Morgan SL, Ha T, Vaughn WH, Hine KJ (1992) Inhibition of folate-dependent enzymes by non-steroidal anti-infalmmatory drugs. Biochem J 282: 197-202.
50. Gadangi P, Longaker M, Naime D, Levin RI, Recht PA, et al. (1996) The anti- inflammatory mechanism of sulfasalazine is related to adenosine release at inflamed sites. J Immunol 156: 1937-1941.
51. Lukashev D, Ohta A, Apasov S, Chen JF, Sitkovsky M (2004) Cutting Edge: Physiologic Attenuation of Proinflammatory Transcription by the Gs Protein-Coupled A2A Adenosine Receptor In Vivo. J Immunol 173: 21-24.
52. Rousseaux C, Lefebvre B, Dubuquoy L, Lefebvre P, Romano O, et al. (2005) Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-{gamma}. J Exp Med 201: 1205-1215.
53. Salh B, Assi K, Huang S, O'Brien L, Steinbrecher U, et al. (2002) Dissociated ROS production and ceramide generation in sulfasalazine-induced cell death in Raw 264.7 cells. J Leukoc Biol 72: 790-799.
54. Oshikawa K, Sugiyama Y (2003) Regulation of toll-like receptor 2 and 4 gene expression in murine alveolar macrophages. Exp Lung Res 29: 401-412.
55. Hasko G, Szabo C, Nemeth ZH, Deitch EA (2001) Sulphasalazine inhibits macrophage activation: inhibitory effects on inducible nitric oxide synthase expression, interleukin-12 production and major histocompatibility complex II expression. Immunology 103: 473-478.
56. Wang J, Gigliotti F, Bhagwat SP, Maggirwar SB, Wright TW (2007) Pneumocystis stimulates MCP-1 production by alveolar epithelial cells through a JNK- dependent mechanism. Am J Physiol Lung Cell Mol Physiol 292: L1495-L1505.
57. Coste A, Dubourdeau M, Linas MD, Cassaing S, Lepert JC, et al. (2003) PPARgamma promotes mannose receptor gene expression in murine macro- phages and contributes to the induction of this receptor by IL-13. Immunity 19: 329-339.
58. Coste A, Lagane C, Filipe C, Authier H, Gales A, et al. (2008) IL-13 attenuates gastrointestinal candidiasis in normal and immunodeficient RAG-2(-/-) mice via peroxisome proliferator-activated receptor-gamma activation. J Immunol 180: 4939-4947.
59. Gales A, Conduche A, Bernad J, Lefevre L, Olagnier D, et al. (2010) PPARgamma controls dectin-1 expression required for host antifungal defense against Candida albicans. PLoS Pathog 6(1): e1000714.
60. Hunter MM, Wang A, Parhar KS, Johnston MJ, Van RN, et al. (2010) In vitro-derived alternatively activated macrophages reduce colonic inflammation in mice. Gastroenterology 138: 1395-1405.
61. Gaut P, Daar ES (1999) Editorial response: Prophylaxis for Pneumocystis carinii pneumonia an evolving tale of two populations. Clin Infect Dis 29: 784-786.
62. Bhagwat SP, Wright TW, Gigliotti F (2010) Anti-CD3 antibody decreases inflammation and improves outcome in a murine model of Pneumocystis pneumonia. J Immunol 184: 497-502.
63. Ezekowitz RA, Williams DJ, Koziel H, Armstrong MY, Warner A, et al. (1991) Uptake of Pneumocystis carinii mediated by the macrophage mannose receptor. Nature 351: 155-158.
64. Forte M, Rahelu M, Stubberfield C, Tomkins L, Pithie A, et al. (1991) In-vitro interaction of human macrophages with Pneumocystis carinii. Int J Exp Pathol 72: 589-598.
65. Koziel H, Eichbaum Q, Kruskal BA, Pinkston P, Rogers RA, et al. (1998) Reduced binding and phagocytosis of Pneumocystis carinii by alveolar macro-phages from persons infected with HIV-1 correlates with mannose receptor downregulation. J Clin Invest 102: 1332-1344.
66. Lasbury ME, Lin P, Tschang D, Durant PJ, Lee CH (2004) Effect of bronchoalveolar lavage fluid from Pneumocystis carinii-infected hosts on phagocytic activity of alveolar macrophages. Infect Immun 72: 2140-2147.
67. Limper AH, Standing JE, Hoyte JS (1996) The role of alveolar macrophages in Pneumocystis carinii elimination from the lower respiratory tract. J Eukaryot Microbiol 43: 12S.
68. Masur H, Jones TC (1978) The interaction in vitro of Pneumocystis carinii with macrophages and L-cells. J Exp Med 147: 157-170.
69. Steele C, Marrero L, Swain S, Harmsen AG, Zheng M, et al. (2003) Alveolar macrophage-mediated killing of Pneumocystis carinii f. sp. muris involves molecular recognition by the Dectin-1 beta-glucan receptor. J Exp Med 198: 1677-1688.
70. Zhang J, Zhu J, Bu X, Cushion M, Kinane TB, et al. (2005) Cdc42 and RhoB activation are required for mannose receptor-mediated phagocytosis by human alveolar macrophages. Mol Biol Cell 16: 824-834.
71. Baskerville A, Dowsett AB, Cook RW, Dennis MJ, Cranage MP, et al. (1991) Pneumocystis carinii pneumonia in simian immunodeficiency virus infection: immunohistological and scanning and transmission electron microscopical studies. J Pathol 164: 175-184.
72. Chen W, Mills JW, Harmsen AG (1992) Development and resolution of Pneumocystis carinii pneumonia in severe combined immunodeficient mice: a morphological study of host inflammatory responses. Int J Exp Pathol 73:709-720.
73. Wehle K, Blanke M, Koenig G, Pfitzer P (1991) The cytological diagnosis of Pneumocystis carinii by fluorescence microscopy of Papanicolaou stained bronchoalveolar lavage specimens. Cytopathology 2: 113-120.
74. Wehle K, Schirmer M, Dunnebacke-Hinz J, Kupper T, Pfitzer P (1993) Quantitative differences in phagocytosis and degradation of Pneumocystis carinii by alveolar macrophages in AIDS and non-HIV patients in vivo. Cytopathology 4: 231-236.
75. Empey KM, Hollifield M, Schuer K, Gigliotti F, Garvy BA (2004) Passive immunization of neonatal mice against Pneumocystis carinii f. sp. muris enhances control of infection without stimulating inflammation. Infect Immun 72: 6211-6220.
76. Weaver T, Hall CL, Kachel DL, Ward RP, Williams MD, et al. (1996) Assessment of in vivo attachment/phagocytosis by alveolar macrophages. J Immunol Methods 193: 149-156.
77. Limper AH, Hoyte JS, Standing JE (1997) The role of alveolar macrophages in Pneumocystis carinii degradation and clearance from the lung. J Clin Invest 99: 2110-2117.
78. Wright TW, Pryhuber GS, Chess PR, Wang Z, Notter RH, et al. (2004) TNF receptor signaling contributes to chemokine secretion, inflammation, and respiratory deficits during Pneumocystis pneumonia. J Immunol 172: 2511-2521.
79. George TC, Basiji DA, Hall BE, Lynch DH, Ortyn WE, et al. (2004) Distinguishing modes of cell death using the ImageStream multispectral imaging flow cytometer. Cytometry A 59: 237-245.
80. Ortyn WE, Hall BE, George TC, Frost K, Basiji DA, et al. (2006) Sensitivity measurement and compensation in spectral imaging. Cytometry A 69: 852-862.
81. Wells J, Gigliotti F, Simpson-Haidaris PJ, Haidaris CG (2004) Epitope mapping of a protective monoclonal antibody against Pneumocystis carinii with shared reactivity to Streptococcus pneumoniae surface antigen PspA. Infect Immun 72: 1548-1556.
82. George TC, Fanning SL, Fitzgeral-Bocarsly P, Medeiros RB, Highfill S, et al. (2006) Quantitative measurement of nuclear translocation events using similarity analysis of multispectral cellular images obtained in flow. Journal of Immunological Methods 311: 117-129.
83. Megjugorac NJ, Jacobs ES, Izaguirre AG, George TC, Gupta G, et al. (2007) Image-Based Study of Interferongenic Interactions between Plasmacytoid Dendritic Cells and HSV-Infected Monocyte-Derived Dendritic Cells*. Immunological Investigations 36: 739-761.